A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Exclusion criteria

• . Participant has an acute illness as defined by any of the following (note: assessment may be repeated once during screening period) as determined by the site investigator, within 72 hours prior to vaccination:
• . An acute illness that is nearly resolved, with only minor residual symptoms remaining, is allowable if, in the opinion of the site investigator, the residual symptoms will not interfere with the ability of study staff to assess safety parameters as required by the protocol.
• . Presence of a fever ≥ 38.0°C (100.4°F) measured orally at baseline, on Day 1 prior to vaccination.
• . Receipt of antipyretic/analgesic medications within 24 hours prior to vaccine administration.
• . Participant has had a positive COVID test within 90 days prior to screening.
• . Current or planned participation in any other interventional clinical trial.
• . Participation in research involving any investigational product within 45 days prior to study vaccination.
• . Receipt of any approved or authorized products intended to prevent SARS-CoV2 infection within 6 months prior to study vaccination.